SynAct Pharma AB - Asset Resilience Ratio

Latest as of December 2022: 0.13%

SynAct Pharma AB (SYNACT) has an Asset Resilience Ratio of 0.13% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check SYNACT PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr180.00K

≈ $19.37K USD Cash + Short-term Investments

Total Assets

Skr142.60 Million

≈ $15.35 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2020–2023)

This chart shows how SynAct Pharma AB's Asset Resilience Ratio has changed over time. See SYNACT equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down SynAct Pharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is SynAct Pharma AB worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr180.00K	0.13%
Total Liquid Assets	Skr180.00K	0.13%

Asset Resilience Insights

Limited Liquidity: SynAct Pharma AB maintains only 0.13% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

SynAct Pharma AB Industry Peers by Asset Resilience Ratio

Compare SynAct Pharma AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for SynAct Pharma AB (2020–2023)

The table below shows the annual Asset Resilience Ratio data for SynAct Pharma AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.04%	Skr93.00K ≈ $10.01K	Skr228.02 Million ≈ $24.54 Million	-0.09pp
2022-12-31	0.13%	Skr180.00K ≈ $19.37K	Skr142.60 Million ≈ $15.35 Million	+1.09pp
2020-12-31	-0.96%	Skr-208.00K ≈ $-22.38K	Skr21.59 Million ≈ $2.32 Million	--

pp = percentage points

About SynAct Pharma AB

ST:SYNACT Sweden Biotechnology

Market Cap

$70.27 Million

Skr652.94 Million SEK

Market Cap Rank

#20673 Global

#372 in Sweden

Share Price

Skr11.66

Change (1 day)

+9.38%

52-Week Range

Skr10.66 - Skr24.95

All Time High

Skr143.40